Related Experiment Video
Updated: Jul 24, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Impaired vision in children prenatally exposed to methadone: an observational cohort study
R Hamilton1, A Mulvihill2, L Butler3
1Royal Hospital for Children, NHS Greater Glasgow & Clyde and the University of Glasgow, Glasgow, G51 4TF, UK. ruth.hamilton@glasgow.ac.uk.
Insights
Children exposed to methadone in utero are nearly twice as likely to experience visual impairments by primary school age. Early visual assessments are recommended for infants with prenatal opioid exposure history.
Area of Science:
- Pediatric Ophthalmology
- Neonatal Abstinence Syndrome Research
- Prenatal Substance Exposure Studies
Background:
- Children born to mothers undergoing methadone maintenance treatment (MMOD) may face developmental challenges.
- Understanding the long-term effects of in utero substance exposure is crucial for early intervention.
Purpose of the Study:
- To determine the prevalence of visual assessment failures in children aged 8-10 years born to MMOD mothers.
- To correlate these visual outcomes with documented in utero substance exposure.
Main Methods:
- An observational cohort study followed methadone-exposed and comparison children.
- Visual assessments evaluated acuity, strabismus, nystagmus, and stereovision.
- Statistical analysis adjusted for confounding variables like maternal tobacco use.
Main Results:
- Methadone-exposed children showed a significantly higher likelihood of visual 'fail' outcomes (adjusted OR 2.6, aRR 1.8).
- No significant difference in visual 'fail' rates was observed between methadone-exposed children who received treatment for neonatal abstinence syndrome (NAS/NOWS) and those who did not.
- Visual assessment failures included reduced acuity, strabismus, nystagmus, and impaired stereovision.
Conclusions:
- Children exposed to methadone prenatally exhibit a nearly twofold increased risk of significant visual abnormalities by primary school age.
- Prenatal methadone exposure should be considered in the differential diagnosis of nystagmus.
- Routine visual screening before school entry is recommended for children with a history of prenatal opioid exposure.
Background/Objectives:
To examine prevalence of failed visual assessment at 8-10 years in children born to methadone-maintained opioid dependent (MMOD) mothers and relate this to known in utero substance exposure.
Subjects/Methods:
Follow up of observational cohort study of methadone-exposed and comparison children matched for birthweight, gestation and postcode of residence at birth. Participants were 144 children (98 exposed, 46 comparison). Prenatal drug exposure was previously established via comprehensive maternal and neonatal toxicology. Children were invited to attend for visual assessment and casenotes were reviewed. Presence of acuity poorer than 0.2 logMAR, strabismus, nystagmus and/or impaired stereovision constituted a 'fail'. Fail rates were compared between methadone-exposed and comparison children after adjusting for known confounding variables.
Results:
33 children attended in person: data were also derived from casenote review for all children. After controlling for maternal reported tobacco use, methadone-exposed children were more likely to have a visual 'fail' outcome, adjusted odds ratio 2.6, 95% CI 1.1-6.2; adjusted relative risk 1.8 (95% CI 1.1-3.4). Visual 'fail' outcome rates did not differ between methadone-exposed children who had (n = 47) or had not (n = 51) received pharmacological treatment for neonatal abstinence/opioid withdrawal syndrome (NAS/NOWS); fail rate 62% vs 53% (95% CI of difference-11-27%).
Conclusions:
Children born to MMOD mothers are almost twice as likely as unexposed peers to have significant visual abnormalities at primary school age. Prenatal methadone exposure should be considered in the differential diagnosis of nystagmus. Findings support visual assessment prior to school entry for children with any history of prenatal opioid exposure.
Trial Registration:
The study was prospectively registered on ClinicalTrials.gov (NCT03603301), https://clinicaltrials.gov/ct2/show/NCT03603301 .
Related Concept Videos
Photoreceptors and Visual Pathways
Teratogenicity

